false
--12-31
0001445815
0001445815
2026-03-12
2026-03-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): March 12, 2026
BIOXYTRAN,
INC.
(Exact
Name of Registrant as Specified in Charter)
| Nevada |
|
001-35027 |
|
26-2797630 |
| (State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
| of
Incorporation) |
|
File
Number) |
|
Identification
Number) |
| 75
Second Ave, Suite 605, Needham, MA |
|
02494 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code 617-454-1199
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| |
|
|
|
|
| Common
Stock, par value $0.001 |
|
BIXT |
|
OTCQB |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.03 – Material Modification to Rights of Security Holders
The
Company approved and filed an amendment to the Certificate of Designation of Convertible Preferred Stock to modify the conversion
provisions of the Company’s Preferred Stock. The amendment was filed with the Nevada Secretary of State on February 18, 2026
and became effective upon filing.
The
amendment provides that no shares of Convertible Preferred Stock may be converted into Common Stock unless such conversion is approved
by both (i) the Board of Directors and (ii) the holders of a majority of the outstanding shares of Preferred Stock voting as a single
class.
The
amendment was approved by the Board of Directors and by the holders of a majority of the outstanding shares of Convertible Preferred
Stock through written consent in accordance with the Certificate of Designation and Nevada law.
This amendment was adopted to ensure
that any conversion of the Company’s Convertible Preferred Stock is subject to appropriate corporate and preferred shareholder
approvals.
Item
5.02 – Compensatory Arrangements of Certain Officers
The
Board of Directors of Bioxytran, Inc. (the “Company”) recently approved a performance-based equity award to David Platt,
the Company’s Chief Executive Officer.
Pursuant
to the Board’s approval, the Company granted 6,000,000 shares of the Company’s Convertible Preferred Stock to Dr. Platt as
a performance grant in recognition of his role in executing the Company’s first commercial distribution agreement and advancing
capital funding initiatives.
The
Board approved the award to align executive incentives with the Company’s commercialization and capital formation objectives.
Item
5.03 – Amendments to Articles of Incorporation
In
connection with the amendment described above, the Company filed a Certificate of Amendment to the Certificate of Designation of Convertible
Preferred Stock with the Nevada Secretary of State on February 18, 2026, which became effective upon filing.
Item
9.01 – Exhibits
3.1
Certificate of Amendment to Certificate of Designation of Convertible Preferred Stock (Filed with the Nevada Secretary of State on February 18, 2026)
104 Cover
Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
BIOXYTRAN,
INC. |
| |
|
|
| |
By: |
/s/
David Platt, Ph.D. |
| |
|
David
Platt, Ph.D., its Chief Executive Officer |
| |
|
|
| Date
March 12, 2026 |
|
